18 March 2016 - Patients with pancreatic cancer living in Wales will no doubt welcome news that Celgene’s Abraxane will continue to be available on the National Health Service in the country, despite a decision by the National Institute for Health and Care Excellence to reject its use.

NICE confirmed back in November that Celgene’s Abraxane (nab-paclitaxel) will not be routinely funded for use in combination with gemcitabine for treating pancreatic cancer on the NHS in England and Wales, claiming that the drug’s cost does not justify its benefit to patients.

For more details, go to: http://www.pharmatimes.com/Article/16-03-18/Welsh_gov_overrules_NICE_rejection_of_Celgene_s_pancreatic_cancer_drug.aspx